What is Evonik's new Vancouver facility intended to produce, and why is this technology significant?

Evonik's new Vancouver facility is intended to produce lipid nanoparticle (LNP) drug delivery systems under Good Manufacturing Practice (GMP) standards. LNPs are described in the article as 'the core delivery technology for mRNA vaccines, cancer immunotherapies and other next-generation drugs.'

When is the new LNP production facility expected to begin operations, and what is its projected scale relative to Evonik's current capacity?

The new facility is expected to begin operations by the end of 2029 and will have a production capacity 'more than three times' that of Evonik's existing facilities, while also significantly enhancing quality control and microbiological testing capabilities to improve product release efficiency.

Evonik to Build New Vancouver LNP Drug Production Facility

Sep 2, 2026

Evonik announced plans to construct a new GMP-compliant LNP drug production facility in Vancouver with over 150 million CAD investment, targeting 2029 completion. The project will triple existing capacity and support the growing mRNA vaccine and immunotherapy markets.

ccin

2025-11-04

Evonik beats estimates despite weaker profits

2026-01-23

Argentina urged to adopt long-term industrialization plan to leverage Vaca Muerta shale wealth – Evonik exec

2026-02-05

Evonik Reports Higher Net Profit in Preliminary Results

2026-02-09

Evonik Launches PFAS-Free Liquid Additives

2026-02-10

Evonik to expand HTPB capacity in Germany